MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
Venture Capital: Virginia
Tall Oaks Capital
MaxCyte, Inc. (NASDAQ:MXCT)*
Organization & Developments: Maxcyte
Parents
MaxCyte, Inc. (NASDAQ:MXCT)*
Children
*Cell based therapetics
*MaxCyte is a clinical stage biotechnology company advancing cell therapy, drug delivery and drug discovery with new cell-loading
*MaxCyte is focused on the development and commercialization of flow electroporation technology.
*MaxCyte, Inc. is active in cell engineering providing technologies to discover, develop and commercialize next-generation cell therapeutics and advance novel and cell-based scientific research
2022; MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program_Biohealth Innovation
2022: MaxCyte Is Poised For A Strong Rebound_ seekingalpha.com
2025: MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price_ seekingalpha.com
2025: Rockville's MaxCyte slashes workforce by 34% amid revenue struggles
Jumps
*Key People: Maxcyte
Finance & Acquisitions: Maxcyte